

Supplemental Tables and Figures

Supplemental Table 1. Clinical characteristics FFPE tissue patient subset

| Parameters | FFPE subset (n = 25) | non-IPMN [§] (n=9) | IPMN (n = 10) | Cancer (n = 6) |
|--|---------------------------|---|----------------------------------|---|
| Gender (F:M) | 13:12 | 8:1*† | 2:8* | 2:4† |
| Age (years) median (range) | 66 (31 – 81) | 48*† (31 – 68) | 66.5* (47 – 78) | 70.5† (65 – 81) |
| BMI (kg/m ²) median (range) | 25.8 (20.2 – 35.0) | 28.0 (23.0 – 35) | 25.3 (21.5 – 30.6) | 25.4 (20.2 – 29.4) |
| Smoking (%) | 12 | 22.2 | 10 | 0 |
| Alcohol (%) | 40 | 44.4 | 40.0 | 33.3 |
| Diabetes (%) | 16 | 0 | 20.0 | 33.3 |
| PPI use (%) | 12 | 22 | 10.0 | 0 |
| S-Ca 19-9 (kE/L) median (range) above normal # (%) | 8.8 (<1.0 – 480) 28 | 7.9† (5.9 – 34) 0† | 5.7 (<1.0 – 71) 10.0 | 315† (63 – 480) 100† |
| HbA1c (mmol/mol) median (range) | 36 (30 – 64) | 33.0 (30 – 43) | 38.5 (32 – 64) | 37.5 (31 – 52) |
| Amylase (µkat/L) median (range) | 0.30 (<0.13 – 2.62) | 0.31 (0.22 – 1.64) | 0.25 (<0.13 – 2.62) | <0.13 (<0.13 – 0.34) |
| Albumin (g/L) median (range) | 36 (28 – 42) | 38.0† (33 – 42) | 36.0 (30 – 42) | 28.5† (28 – 36) |
| Bilirubin (µmol/L) median (range) | 6 (<3 – 119) | 5† (<3 – 18) | 6 (<3 – 17) | 14† (5 – 119) |
| CRP (mg/L) median (range) | 2 (1 – 130) | 2 (1 – 13) | 1 (1 – 49) | 17 (2 – 130) |
| Invasive endoscopic procedure (%) mean freq. (range) | 48 0.8 (0 – 3) | 11.1† 0.11 (0 – 1) † | 50.0 1 (0 – 3) | 100† 1.5 (1 – 3) † |
| Uni-/Multicystic (%) | 68/32 | 88.8/11.1 | 40/60 | 83.3/16.6 |

[§] non-IPMN group comprises of MCN (n=3) and SCN (n=6)


normal S-Ca 19-9 < 34 kE/L

Pairwise comparisons between the diagnosis groups were made using Fisher's exact test (qualitative parameters) and Kruskal-Wallis test with Dunn's multiple comparisons correction (quantitative variables).


* indicates "non-IPMN cyst" vs "IPMN" p < 0.05 (two-tailed)

† indicates "non-IPMN cyst" vs "Cancer" p < 0.05 (two-tailed)


n.a. = not applicable



Supplemental Figure 1. A) Quantification of bacterial lipopolysaccharide (LPS) in cyst fluid from "non-IPMN" (n=5), "IPMN" (n=24), "IPMN Cancer" (n=5) patients. **B)** Spearman correlation analysis on intracystic 16S DNA copies and LPS quantities. **C)** Spearman correlation analysis on intracystic IL-1 β and LPS quantities. Statistically significant differences were determined using Kruskal-Wallis test with Dunn's multiple comparison test with * $p < 0.05$. LLD = lower limit of detection, ULD = upper limit of detection.



Supplemental Figure 2. Intracystic quantity of bacterial 16S DNA in **A**) patients who never underwent IEP in “SCN” (n=10), “IPMN LGD” (n=31), “IPMN HGD and Cancer” (n=16) patient group, and **B**) in all patients of “SCN” (n=12), “IPMN LGD” (n=43), “IPMN HGD and Cancer” (n=41) patient group. Bars indicate mean for 16S DNA quantity. Spearman correlation analysis on 16S DNA and IL-1 β quantities in cyst fluid in **C**) patients who never underwent IEP, and **D**) patients that had history or prior IEP. Statistically significant differences were determined using Mann-Whitney test.



Supplemental Figure 3. Sub-analysis of microbial relative abundance data allowing one sample per patient (n=35) **A**) Cladogram representing LEfSe results which identified 10 features that are differentially abundant between the three diagnose classes (red = Cancer, orange = IPMN HGD, yellow = IPMN LGD). **B,C,D,E,F,G**) Violin plot showing relative abundance distribution and median of selected differentially abundant bacterial genera per diagnose group.